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ABSTRACT
Objectives: In the Gambia, the combination of chloroquine (CQ) and sulphadoxine-
pyrimethamine (SP) has replaced CQ monotherapy for treatment of malaria caused by
Plasmodium falciparum. We measured the efficacy of the combination CQ/SP, and the
prevalence of parasites carrying alleles associated with resistance to CQ or SP.
Design: We conducted a single-blind, randomised, controlled trial to compare the efficacy of
CQ/SP to that of SP or CQ alone.
Setting: The study took place in the town of Farafenni and surrounding villages in the
Gambia.
Participants: Participants were children aged 12 mo to 10 y presenting as outpatients with
uncomplicated P. falciparum malaria.
Interventions: 500 children were randomised to receive CQ, SP, or CQ/SP as supervised
treatment and actively followed over 28 d.
Outcome Measures: Primary outcome was parasitaemia at any time during follow-up.
Secondary outcomes were PCR-confirmed recrudescent infections among treatment failures,
and clinical failure requiring rescue medication by day 28. Pretreatment parasite isolates from
161 patients were tested for the presence of resistance-associated genetic markers.
Results: The prevalence of parasitological failure by day 28 for the CQ group was 60.3%,
compared to 17.6% for SP (odds ratio [OR], 0.106; 95% confidence interval [CI], 0.057–0.194; p,
0.001) and 13.9% for CQ/SP (OR versus CQ, 0.140; 95% CI, 0.078–0.250; p, 0.001). There was no
difference between the SP and CQ/SP groups (OR, 1.324; 95% CI, 0.705–2.50). The projected
prevalence of PCR-corrected treatment failure was 30.2, 6.06, and 3.94% in the CQ, SP, and CQ/
SP groups, respectively. The pfdhfr-triple mutant and pfdhps-437G mutation were common,
with prevalences of 67.4 and 51.2%, respectively. Pretreatment carriage of pfdhps-437G and of
multidrug-resistant parasite genotypes was associated with treatment failure in the SP group,
but not in the CQ or CQ/SP groups.
Conclusions: The combination of CQ/SP was an efficacious treatment for uncomplicated
malaria in Gambian children in this study, but the frequent occurrence of multidrug-resistant
parasites suggests that this observed efficacy is not sustainable.
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INTRODUCTION
Malaria control in Africa has until recently relied heavily on
chemotherapy with chloroquine (CQ), a cheap and safe
antimalarial drug [1,2]. CQ remains widely distributed and
readily available even in the most remote villages in sub-
Saharan Africa. In the Gambia, each village with a population
of 400 or more has a trained village health worker who is
provided with chloroquine and other basic drugs [3].
Chloroquine-resistant strains of Plasmodium falciparum, ﬁrst
observed in East Africa in 1987, have now been reported in all
countries of tropical Africa [4].
Studies between 1994 and 2000 found that 65–73% of
Gambian children treated with chloroquine were parasitae-
mic at some point over 28 days of follow-up [5,6],
demonstrating that as in much of Africa, CQ had ceased to
be a satisfactory ﬁrst-line treatment for uncomplicated P.
falciparum malaria and an alternative was urgently required
[7]. There have been a number of trials in sub-Saharan Africa
to measure the efﬁcacy, effectiveness, and impact on trans-
mission of a variety of combination antimalarial regimens,
including those incorporating a member of the artemisinin
family [6,8–14]. Although the use of these newer combina-
tions as ﬁrst-line treatment for malaria is being adopted as
policy in many African countries, interim solutions have been
urgently sought by some prior to the full-scale introduction
of artemisinin-based combination therapy.
In the Gambia, the combination of CQ and sulfadoxine-
pyrimethamine (SP) has been shown to be a more effective
symptomatic treatment than SP alone for malaria [8]. CQ/SP
has therefore been used increasingly in the face of spreading
resistance to CQ, and the combinationwas ofﬁcially adopted as
an affordable alternative frontline therapy in 2004. However,
few reliable data are available on the efﬁcacy of the combina-
tion CQ/SP in the Gambia, and although recent work has
described the contribution of mutations in the CQ-resistance-
associated loci pfcrt and pfmdr1 to CQ treatment failure, to
enhanced transmission to mosquitoes, and to an excess of
severe malaria among rural Gambian children (15–17), there
are no recent Gambian studies examining the prevalence of
mutations associated with SP resistance, in the pfdhfr and pfdhps
genes, nor of their effect on treatment outcome.
This paper reports the result of a randomised controlled
trial conducted in 2001 to evaluate the efﬁcacy of CQ/SP
compared to SP or CQ alone. We also measured the
pretreatment prevalence of parasites carrying resistance-
associated alleles of four genes previously implicated in
treatment failure of CQ and SP, and evaluate their
contribution to therapeutic outcome.
METHODS
Participants
The study took place from September to December 2001 in
Farafenni, a rural town on the north bank of the Gambia
River. It is located on the Senegal border about 170 km from
the Atlantic coast. The town has been the site for clinical
trials to determine the efﬁcacy of antimalarial drug combi-
nations with gametocyte carriage and transmission as major
endpoints since 1998 [6,10,11,13,14]. The climate is character-
istic of the sub-Sahel with a short rainy season from mid-June
to mid-October. Malaria is thus seasonal with most clinical
episodes occurring during a limited period of 8 to 10 wk at
the end of the rains.
Recruitment took place at the Maternal and Child Health
clinic according to an established protocol [6]. Brieﬂy,
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Editorial Commentary
Background: Throughout Africa, the readily available and cheap
antimalarial drug, chloroquine, has been failing as a good first-line
treatment for uncomplicated malaria. This is mainly due to the malaria
parasite becoming resistant to treatment. Many African countries are
now adopting newer artemisinin-based combination therapies as first-
line treatment. However other countries have put interim solutions in
place before introducing artemisinin-based drugs. The combination of
chloroquine and sulfadoxine-pyrimethamine was officially adopted as
first-line therapy in the Gambia in 2004. However, little data exists on the
efficacy of this combination in that setting. It is also not known whether
parasites resistant to sulfadoxine-pyrimethamine, as well as chloroquine,
are common in the Gambia. In this trial, conducted in a rural town in the
Gambia in 2001, the researchers randomized 500 young children
presenting with uncomplicated P. falciparum malaria to receive either
chloroquine, sulfadoxine-pyrimethamine, or the combination of both
treatments. The researchers then looked for the presence of parasites in
the blood of treated children over 28 days of follow-up. Infections
following treatment were defined as either the same infection that was
originally treated (a recrudescence) or a new infection. The need for
rescue medication, indicating clinical failure, was also examined.
What the trial shows: In this trial, both sulfadoxine-pyrimethamine and
the combination of chloroquine and sulfadoxine-pyrimethamine were
more effective at clearing parasites from the blood than chloroquine
alone. However the combination of chloroquine and sulfadoxine-
pyrimethamine appeared to be equivalent to sulfadoxine-pyrimeth-
amine in clearing parasite infection. When the researchers distinguished
parasite infections into recrudescences or new infections, they found
that either treatment option containing sulfadoxine-pyrimethamine
prevented a recurrence of the original infection better than treatment
with chloroquine. Clinical failure was also higher amongst children
treated with chloroquine than those treated with sulfadoxine-pyri-
methamine alone or the combination. In children treated with
chloroquine and sulfadoxine-pyrimethamine, parasite infection was
found in 14% of participants at 28 days of follow-up. A number of
children carried parasites predicted to be resistant to both chloroquine
and sulfadoxine-pyrimethamine. However, these children were not
significantly more likely to fail treatment.
Strengths and limitations: The trial took place in an area where there is,
to date, little data on the efficacy of the different treatment regimens
studied. The trial is also part of an ongoing series of other studies, which
will ultimately allow researchers to detect changes in the efficacy of
different treatments over time, providing information about parasite
selection and the useful therapeutic life of particular treatments.
However, the loss to follow-up in this trial was high (between 25 and
32%, depending on the treatment arm) due to logistical constraints
around the time of the Gambian national election. It is not possible to
tell if data from the participants lost to follow-up would have changed
the overall conclusions.
Contribution to the evidence: This study provides additional data
about the efficacy of chloroquine / sulfadoxine-pyrimethamine treat-
ment in the Gambia, as compared to chloroquine or sulfadoxine-
pyrimethamine alone. Prior evidence was not strong enough to confirm
the advantage of chloroquine / sulfadoxine-pyrimethamine over
chloroquine alone. The identification of parasites resistant to both
chloroquine and sulfadoxine-pyrimethamine indicates that new combi-
nation drugs are needed in this part of Africa.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.
children 0.5–10 y of age living within 15–20 km radius of
Farafenni who presented to the Maternal and Child Health
clinic or the General Hospital with history of fever and/or
current fever (axillary temperature, 37.5 8C) and other
symptoms suggestive of acute malaria infection, a carriage of
P. falciparum parasites at a density ranging between 500 and
250,000 parasites/ll of blood, and a packed cell volume (PCV)
20% were enrolled in the study after obtaining the free and
informed consent of their parents or guardians. Excluded from
the study were children with anaemia (PCV, ,20%), any signs
or symptoms of severe malaria, inability to take drugs orally or
any evidence of chronic disease, malnutrition or any other
acute infection, including non-falciparummalaria. If there was
evidence of treatment with any antimalarial drug within the
past 2 wk, either from notes on the clinic card carried by
children under 5 y of age, or after questioning of the caregiver,
the child was excluded. The study protocol was reviewed and
approved by the Medical Research Council/Gambian Govern-
ment Joint Ethics Committee, and the Ethics Committee of the
London School of Hygiene and Tropical Medicine.
Interventions
We performed a single-blind, randomised, controlled trial of
oral treatment of uncomplicated falciparum malaria with
CQ, SP, and the combination CQ/SP. A thorough clinical
history (including demographic data) was taken, and a
medical examination was performed by a study clinician on
the day of screening, day 0. At screening and at each visit,
body temperature was measured with a digital thermometer
(Toshiba, Tokyo, Japan). The treatments used were CQ alone
(25 mg of CQ base per kilogram of body weight over a 3-d
period: 10 mg/kg on days 0 and 1; 5 mg/kg on day 2), SP alone
given in a single dose (25 mg/kg sulphadoxine/1.25 mg/kg
pyrimethamine), or the combination of CQ/SP. The group
sizes were 130:180:200, respectively. This ratio was derived a
priori as likely to ensure sufﬁcient power for both efﬁcacy
and transmission endpoints of the trial, taking into account
that children randomised to receive SP were further divided
into three groups according to the day of the week on which
they were recruited, as part of the accompanying study of
post-treatment transmission [18]. These three SP-treated
groups differed in their follow-up schedule, and only SP-
treated patients recruited on Thursday or Friday received
identical follow-up to children receiving CQ or CQ/SP.
Therefore, only these patients are included in the analysis
of clinical efﬁcacy (Figure 1). Treatment allocation and
prescription of the required medication were performed by
a study clinician, and medicines were administered by a study
Figure 1. CONSORT Flowchart
A total of 1,366 children was screened, and 500 were randomised. Children randomised to receive SP on Thursday or Friday (N¼79), were scheduled for standard
follow-up and thus fulfilled the criteria for efficacy evaluation. Follow-up data are shown for these 79, but not for the other SP-treated children. Shaded boxes
represent gametocyte screening days [18].
DOI: 10.1371/journal.pctr.0010014.g001
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nurse. Treatment was performed in a separate room but was
not deliberately obscured from the view of the study team.
Older children chewed or swallowed the tablets whole with
water. For younger children, the tablets were crushed
together in a cup and mixed with water before administra-
tion. Subsequent doses, for those in chloroquine groups, were
supervised by trained ﬁeld assistants in the patients’ homes.
All treated children were observed for 30 min, and any child
who vomited was administered a replacement dose. Children
who vomited both the initial and the repeat medication were
excluded from the study and either given parenteral CQ,
which at the time of the study was standard care in the
Gambia for children with uncomplicated malaria who could
not retain oral medication, or admitted to the paediatric
ward of Farafenni Hospital.
In addition to the study drugs, oral paracetamol (10 mg/kg,
three times daily) was given together with the study
medication in the clinic, and additional doses (to last for 3
d) were given to parents/guardians for administration to their
children at home.
Objectives
The principal objective was to assess the efﬁcacy of SP and
CQ/SP for the treatment of uncomplicated falciparum
malaria in children, compared to the efﬁcacy of CQ
monotherapy. A secondary objective was to estimate the
prevalence of alleles of parasite genes associated with
resistance to CQ and SP.
Outcomes
The primary outcome was parasitaemia at any time during
follow-up. Secondary outcomes were PCR-corrected group
estimates of treatment failure, and clinical failure requiring
rescue medication by day 28. Pretreatment parasite isolates
from 161 patients were tested for the presence of resistance-
associated genetic markers.
Sample Size
The sample size required in each treatment group was
estimated with transmission endpoints in mind. We expected
to enroll approximately 500 patients, based on data from
1998–2000. In our previous studies, the observed prevalence
of gametocyte carriage 7 d after treatment with SP was .70%
(excluding those who had gametocytes on day 0), and 40%
after treatment with CQ [13]. We therefore expected that the
prevalence of gametocytes after SP/ CQ would be at least 28%
(i.e., 40%3 70%). Based on these ﬁgures, and to ensure that
at least 30 mosquito feeds were performed in each treatment
group, we set out to enroll (a) 200 subjects in the CQ þ SP
group, (b) 50, 60, and 70 subjects in the three groups receiving
SP and being screened for gametocytes on days 7, 10, and 14,
respectively, and (c) 130 subjects in the CQ group. All CQ-
and CQ/SP-treated children were to be screened for
gametocytes on day 7 only. This sample size was expected
to provide sufﬁcient power at the 90% conﬁdence level to
detect a 10-fold difference in infectiousness at day 7 between
gametocyte-positive children treated with SP alone, and those
treated with SP þ CQ [18]. This was not expected to provide
sufﬁcient power to detect any difference in parasitological
efﬁcacy between SP and CQ/SP, which was estimated a priori
to be approximately 90% for both regimens.
Randomisation—Sequence Generation
Eligible patients were randomly assigned to treatment using a
predetermined computer generated randomisation list. The
list was generated by a statistician not otherwise engaged in
the study.
Randomisation—Allocation Concealment
Allocation was not concealed, but taken from a list with 550
allocations on it, in the order of recruitment. Access to this
list was restricted.
Randomisation—Implementation
Patients underwent initial clinical and parasitological screen-
ing to conﬁrm a diagnosis of malaria before being asked for
informed consent by a ﬁeld worker able to speak Wolof,
Mandinka, and Fulani. This person did not have access to the
allocation list. If consent was given, a clinical examination,
treatment allocation, and prescription of the required
medication were performed in a separate room by a study
clinician who had access to the randomisation list.
Randomisation—Blinding
Only the study clinician responsible for initial recruitment
and treatment, and the ﬁeld assistants visiting the children
during follow-up, had knowledge of drug allocations. Field
assistants did not have access to the full allocation list, but
knew the treatment group of children in their care. All
laboratory staff, microscopists, entomologists, and the prin-
cipal investigator were blinded to treatment allocations.
Post-Treatment Follow-Up
Field assistants visited children at home on days 1 and 2 to
supervise treatment (to those in CQ groups) and on days 3,
14, and 28 to enquire from the caretaker about the child’s
condition of health and to collect ﬁnger prick samples that
provided thick blood ﬁlms for microscopy and ﬁlter paper
blood spots for parasite typing by PCR. If on any of these
visits the caretaker was concerned about the child’s health, he
or she was asked to attend the clinic as soon as possible.
Parents/guardians were also requested to bring their children
to the Maternal and Child Health clinic at any time in the
event of clinical aggravation. If a parent or guardian reported
that a child was unwell, the child was examined by a study
clinician. If the child had parasitaemia and fever (axillary
temperature, 37.5 8C) or recent history of fever and did not
have other conditions that could explain the symptoms, and
fewer than 29 d had elapsed since recruitment, the child was
considered a clinical treatment failure and given rescue
treatment as follows: those in the CQ treatment group
received SP, and those in the other two groups received a
standard course of oral quinine. Children presenting with
persistent symptoms of malaria within 3 d of enrollment with
.90% reduction in parasitaemia were not considered to be
clinical treatment failures, and did not receive rescue
treatment. They were monitored until complete recovery.
On day 7 after treatment, the children were collected from
their homes and taken to the Medical Research Council Field
Station in Farafenni where they were clinically examined and
ﬁnger prick blood samples were obtained for thick blood ﬁlm
preparation and PCV estimation. The blood ﬁlms were
stained with Field’s stain and read immediately for malaria
parasites. Some children identiﬁed as gametocyte carriers at
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this time contributed to transmission experiments described
elsewhere [18].
Blood Sampling and Laboratory Measurements
At screening and at day 3, 7, 14, and 28 follow-up visits, blood
samples were obtained by ﬁnger prick for thick blood smears
for malaria microscopy. At day 7, or any time that the child
had symptoms consistent with clinical malaria, two thick
smears were made; the ﬁrst was stained with Field’s stain and
read immediately. The second was dried overnight, stained
with Giemsa, and read later by two experienced laboratory
assistants to provide deﬁnitive parasite counts. One hundred
high-power ﬁelds were read before a slide was declared
negative. At screening and at day 7, blood samples were
collected in heparinised capillary tubes and spun using a
micro-haematocrit centrifuge (Hawksley, West Sussex, United
Kingdom) for PCV determination. Staff performing all
laboratory investigations were blinded to treatment regimens.
Molecular Genotyping
P. falciparum genotypes circulating in children with detectable
asexual parasitaemia during posttreatment follow-up were
compared with those present in the same child prior to
treatment. DNA was extracted from dried blood spots using a
Chelex-based method [19]. Alleles of the polymorphic locus
pfmsp2 were compared between pretreatment and posttreat-
ment parasite isolates by PCR [11,20]. The procedure of
Cattamanchi et al. [21] was followed, in that indeterminate
samples in which a majority of novel bands appeared in the
posttreatment infection were scored as new infections.
Resistance-associated loci encoding amino acid positions
72–76 in pfcrt (sensitive allele, Cys-Val-Met-Asn-Lys [CVMNK];
resistant allele, Cys-Val-Ile-Glu-Thr [CVIET]), position 86 in
pfmdr1 (resistant allele, Asn [N]; sensitive allele, Tyr [Y]),
positions 51, 59, and 108 in pfdhfr (resistant alleles, Ile, Arg,
and Asn [I, R, N], respectively; sensitive alleles, Asn, Cys, and
Ser [N, C, S], respectively), and positions 437 and 540 in pfdhps
(sensitive alleles, Ala and Lys [A, K], respectively; resistant
alleles, Gly and Glu [G, E], respectively) were identiﬁed as
previously described [15,22,23]. Brieﬂy, ﬂuorescent-labeled
oligonucleotide probes speciﬁc for each allele of interest
were hybridised to PCR products spotted in 123 8 arrays on
nylon membranes, and hybridisation signals were detected by
chemiluminescence.
Statistical Methods
All data were double entered and veriﬁed using Epi-Info,
version 6 (Centers for Disease Control and Prevention,
Atlanta, Georgia, United States) and transferred to Stata 7.0
(Stata Corporation, College Station, Texas, United States) for
statistical analysis. All children with follow-up data were
included in the primary analysis. Any child presenting with
danger signs on days 0–3 in the presence of malaria parasites
or fever/history of fever plus parasitaemia any time from days
4 to 28 was given rescue medication and treated as a clinical
therapeutic failure. Proportions were compared using the v2
statistic for parasitological data (denominators .50 in each
case) or using Fisher exact test for clinical failure data and
molecular genotyping data, because in both these analyses
expected proportions in some cells of 2 3 2 tables were 5.
Asexual parasite density was compared between groups using
the ratio of arithmetic means. This was done by ﬁtting
generalized linear models with the negative binomial distri-
bution family and logarithmic link function of the (arith-
metic) mean parasite density as previously described [11].
Conﬁdence intervals around projected relative risk estimates
were calculated from the variance of the log relative risk as
described [24], after modiﬁcation to allow for each risk being
the product of two proportions.
RESULTS
Recruitment and Participant Flow
A total of 1,368 children was screened. Two records were
without parasitaemia data and were therefore excluded from
further analysis. Of the 1,366 children with complete
information on malaria infection, 844 (61.8%) were positive
for malaria parasites according to microscopy at the
recruiting clinic, and were therefore eligible for enrolment
into the study. Of these, 500 were enrolled into the trial; 126,
181, and 193 in the CQ alone, SP alone, and CQ/SP groups,
respectively. The most common reasons for ineligibility for
enrollment were low density parasitaemia (,500/ll of blood)
(n ¼ 114), refusal to give parental consent (n ¼ 40), anemia
.......................................................................................
Table 1. Baseline Demographic and Clinical Characteristics of
Patients Randomised to CQ Alone, SP Alone, or CQ/SP
Treatment
Characteristics Treatment Group
CQ SP CQ/SP
Number (male/female) 126 (61/65) 180 (94/86) 193 (106/87)
Age in years, mean (SD) 4.8 (2.5) 4.8 (2.2) 4.7 (2.3)
Body weight (kg), mean (SD) 15.1 (5.4) 15.5 (5.7) 15.5 (5.1)
Axillary temperature (8C),
mean (SD)
37.7 (5.9) 38.2 (6.8) 38.2 (3.7)
PCV %, mean (SD) 30.2 (4.6) 30.7 (4.9) 30.5 (5.3)
P. falciparum density,
geometric mean per ll
(95% CI)
25,587
(18,835–34,760)
26,186
(21,093–32,508)
30,069
(24,170–37,407)
DOI: 10.1371/journal.pctr.0010014.t001..
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Table 2. Clinical Failure Rates in Children Treated with CQ, SP,
or CQ/SP for Uncomplicated P. falciparum Malaria
Days after Treatment
(Number at Risk Seen in
Each Treatment Group)
Number (%) Receiving Rescue
Medication after Treatment with:
CQa SPa CQ/SPa
0–3 (111, 67, 168) 1 (0.9%) 3 (4.5%) 2 (1.2%)
4–7 (108, 43, 153) 17 (15.0%) 3 (7.0%) 3 (2.7%)
8–14 (82, 45, 140) 4 (4.9%) 0 (0.0%) 0 (0.0%)
15–28 (76, 43, 128) 3 (4.0%) 1 (2.3%) 2 (1.6%)
Total 25/111 (22.5%) 7/67 (10.4%) 7/168 (4.2%)
OR (95% CI) 2.49 (0.92–7.24) 1.00 (ref) —
p ¼ 0.046*
6.68 (2.66–18.9) 2.68 (0.764–9.34) 1.00 (ref)
p , 0.001 p ¼ 0.122
a Denominator in each case is the number of children at risk seen during the time
period. Only those SP-treated children receiving the standard follow-up were included
in this analysis.
* Two-sided Fisher exact test.
Statistically significant p values are indicated in bold.
DOI: 10.1371/journal.pctr.0010014.t002..
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(PCV, ,20%) (n¼ 34), residence outside the clinic catchment
area (n¼ 24), high density parasitaemia (250,000 parasites/ll
of blood), and/or other severe signs of malaria (n ¼ 18) and
presence of concomitant diseases and other reasons (n¼ 51).
A trial proﬁle is shown in Figure 1. Loss to follow-up by day
28 was 25.4, 31.5, and 32.6% in the CQ, SP, and CQ/SP
treatment groups, respectively.
Baseline Data
There were no differences in baseline demographic charac-
teristics or malaria infection between the treatment groups
(Table 1).
Outcomes and Estimation
Clinical outcomes and adverse advents. The frequency of
posttreatment, parasitologically conﬁrmed clinical malaria
(clinical failure) among evaluable study patients in each
treatment group is shown in Table 2. By day 28, as expected
from previous studies, more children in the CQ treatment
group had experienced an episode of clinical malaria
posttreatment than in either of the other groups. There was
weak evidence that clinical failure was more common among
SP-treated children than among those receiving CQ/SP (OR,
2.68; 95% CI, 0.764–9.34). This was apparently due to
persistence of symptoms during the ﬁrst 3 d (Table 2),
consistent with the ﬁndings of Bojang et al. [8]. However,
clinical endpoints were not the main focus of the trial, and we
did not collect sufﬁcient data to make a valid comparison
with earlier results [8]. There were no serious adverse events
reported during follow-up, and no deaths among the 500
recruited participants during the study period.
Parasitological outcomes. The point prevalence of para-
sitological treatment failure for each treatment group at each
day of follow-up is shown in Figure 2. This is a per protocol
analysis. At each time point, parasitological failures were most
common among CQ-treated children, with an uncorrected
cumulative treatment failure rate over 28 d of 60.3% for CQ,
compared to 17.6% for SP (OR, 0.106; 95%CI, 0.057–0.194; p,
0.001) and 13.9% for CQ/SP (OR compared to CQ, 0.140; 95%
CI, 0.078–0.250; p , 0.001). To compare the parasitological
outcomes of each group in more detail, the ratio between
arithmetic mean parasite densities at each day of active follow-
up was calculated, and the statistical signiﬁcance of this
difference tested by negative binomial regression, including
those with zero parasites (Table 3). We have previously used
this method to compare gametocyte densities among treat-
ment groups [11,14]. We found that the parasitological efﬁcacy
of SP was signiﬁcantly higher than that of CQ at days 7, 14, and
28, and that of CQ/SP was signiﬁcantly higher than that of CQ
at days 3, 7, and 14 (Table 3). No signiﬁcant difference in mean
parasite density was found between the SP and CQ/SP groups
at any point (data not shown).
Correction of Parasitological Failure Rates by Msp2
Genotyping
Alleles of msp2 in pretreatment DNA samples were compared
to those in posttreatment DNA samples to distinguish
recrudescent parasites from parasites newly emergent from
the liver during follow-up, as previously described [11]. PCR
was performed for paired isolates from 20 patients with
posttreatment parasitaemia from each treatment group, and
interpretable data obtained for 16, 15, and 17 pairs from the
CQ, SP, and CQ/SP groups, respectively. Results are tabulated
in Table 4, and used to estimate the true failure rate in each
group by extrapolation. We found a corrected failure rate for
CQ of 30.2%, for SP of 6.06%, and for CQ/SP of 3.94%. Using
these estimates, we also projected a ‘‘virtual’’ relative risk of
posttreatment recrudescence in each treatment group (Table
4). Both treatment groups containing SP were substantially
better than CQ monotherapy in this analysis, whereas there
was no signiﬁcant beneﬁt identiﬁed for CQ/SP over SP alone.
Baseline Prevalence of Resistance-Associated Alleles
The prevalence of drug resistance-associated mutations at
seven loci in four genes was measured among 90 day 0
samples randomly selected from among all trial participants
(Figure 3). The prevalence of the pfdhfr triple mutant 51-I, 59-
R, 108-N (IRN) was also measured, as was prevalence of the
combination genotype pfcrt-76T, pfmdr1-86Y, pfdhfr-59R, and
pfdhps-437G (TYRG), a possible multidrug-resistant genotype.
Combination genotypes IRN and TYRG were assigned to
infections in which each allele was present. However, in some
such individuals, wild-type alleles were also present at some of
the loci in the combination, and so it is possible that IRN or
TYRG did not occur as a single haplotype. Of the 60 patients
Figure 2. Point Prevalence of Plasmodium falciparum Asexual Para-
sitaemia 3, 7, 14, and 28 Days after Treatment of Children with CQ, SP, or
CQ/SP
Error bars represent the upper 95% confidence limit of the proportion.
Denominators for these data are (for CQ, SP, and CQ/SP groups, respectively):
day 3, 111, 160, 168; day 7, 107, 52, 152; day 14, 98, 134, 143; and day 28, 94,
124, 130.
DOI: 10.1371/journal.pctr.0010014.g002
.......................................................................................
Table 3. Parasitological Benefit of SP and CQ/SP Treatment
Compared to CQ Treatment at Each Point of Follow-Up
Ratio of Mean Parasite
Density versus CQ
95% CI p
Day 3 SP 0.339 0.097–1.18 0.090
CQ/SP 0.247 0.072–0.850 0.027
Day 7 SP 0.014 0.001–0.152 ,0.001
CQ/SP 0.002 0.0004–0.014 ,0.001
Day 14 SP 0.050 0.004–0.549 0.014
CQ/SP 0.037 0.004–0.397 0.006
Day 28 SP 0.178 0.032–1.00 0.050
CQ/SP 0.240 0.044–1.32 0.101
Denominators are as in Figure 3.
Statistically significant p values are indicated in bold.
DOI: 10.1371/journal.pctr.0010014.t003..
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designated as IRN, 49 (81.7%) unequivocally harboured true
triple-mutant haplotypes, whereas the other 11 patients were
of mixed genotype at two or three of the dhfr resistance-
associated loci. Of the 17 patients who harboured parasites
carrying the mutations pfcrt-76T, pfmdr1-86Y, pfdhfr-59R, and
pfdhps-437G, the resistant allele alone was detected at three or
four of these loci in 11 cases (64.7%). Thus, we are certain
that parasites of the haplotype TYRG must occur in these
infections. Mixed sensitive and resistant alleles were detected
at two loci in four further isolates, and at three and all four
loci in the remaining two isolates, respectively. Thus, in these
latter six isolates, the haplotype TYRG may occur, but this is
not certain. All were retained in subsequent analysis of
associations with treatment failure.
Resistance-Associated Alleles and Treatment Failures
The risk of treatment failure associated with resistant
genotypes at presentation was investigated by examining
resistance-associated loci in pretreatment isolates from 100
patients who subsequently failed treatment. These comprised
44 children who received CQ, 31 who received SP, and 25 who
received CQ/SP, of which four, three, and three children,
respectively, required rescue treatment at the time of failure
due to recurrent or persistent clinical signs of malaria. The
prevalence of each marker in these pretreatment samples was
compared to the prevalence among 61 isolates from children
who were successfully treated. These children, 7, 22, and 32,
respectively, from the CQ, SP, and CQ/SP groups, were
among the 90 randomly selected isolates described in Figure
3. Because 29 of these children subsequently failed treatment,
only 61 were used for the purposes of estimating the odds of
failure associated with each pretreatment genotype. A major
purpose of these exploratory analyses was to identify a
haplotype adequately representing ‘‘multidrug resistance’’
that could be deﬁned at a single locus for each gene and so
did not require using data at all seven loci. Estimates of the
association between treatment failure and both single locus
and selected multilocus genotypes is presented in Table 5.
The only statistically signiﬁcant association with treatment
failure for any single locus was in the SP treatment group,
where children presenting with the pfdhps-437G allele were
more likely to fail treatment than those carrying the wild-type
.......................................................................................................................................................................................
Table 4. Cumulative 28-d Parasitological Failure Rates Corrected by msp2 Genotyping
Treatment
Group (N)a
A
Number Parasitological
Failures; Rate (95% CI)
B
Number of Isolates
Tested (%)
C
Proportion
Recrudescent
A 3 C:
Fail Estimate
(Projected N)
Projected Relative
Riskb (95% CI)
CQ (116) 70; 60.3%
(51.3–69.4%)
16 (23%) 50.0% 30.2% (35) 1.0
SP* (165) 29; 17.6%
(11.7–23.4%)
15 (52%) 33.3% 6.06% (10) 0.194 (versus CQ) (0.076–0.497)**
1.44 (versus CQ/SP) (0.459–4.49)
CQ/SP (173) 24; 13.9%
(8.67–19.1%)
17 (71%) 29.4% 3.94% (7) 0.135 (versus CQ) (0.051–0.357)**
a All treated individuals seen at least once during follow-up included.
b Calculated using the projected number of failures, with column 1 denominators.
* All SP-treated individuals seen at least once during follow-up are included.
** p , 0.001.
DOI: 10.1371/journal.pctr.0010014.t004..
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Figure 3. Prevalence of Resistance-Associated Loci among 90 Pretreatment Parasite Isolates
Genotypes at seven loci in four P. falciparum genes were determined, as was the prevalence of the pfdhfr triple-mutant IRN, and of the putative multidrug-
resistant genotype TYRG.
DOI: 10.1371/journal.pctr.0010014.g003
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437A allele (Table 5). Other weak associations could be
discerned in the data, but given the multiple testing
performed, these ﬁndings were not considered reliable. The
combined dual locus genotype TY deﬁned at pfcrt-76 and
pfmdr1-86, previously associated with CQ treatment failure in
this population [15], appeared to associate with treatment
failure in the SP group only. The combined dual-locus
genotype RG deﬁned at pfdhfr-59 and pfdhps-437 was strongly
associated with treatment failure, also in the SP group only,
suggesting that the combination of these two alleles comprise
the dominant SP-resistant haplotype in this study area. The
four locus genotype combining both of these two allele
genotypes, TYRG, was also strongly associated with treatment
failure only in the SP treatment group (Table 5).
DISCUSSION
Interpretation
In this study, we have examined the efﬁcacy of the
combination CQ/SP for treating uncomplicated falciparum
malaria in Gambian children, compared to either CQ or SP
alone. Pairwise comparisons of parasitological outcomes
between regimens at each point of follow-up demonstrated
a sustained beneﬁt of treatment with SP or CQ/SP compared
to CQ alone, but no difference in efﬁcacy was found between
the two SP-containing treatment groups at any time point.
Cumulative failure rates, after correction by msp2 genotyping
to estimate rates of recrudescence, did not differ between the
SP- and CQ/SP-treated groups of patients. The clinical failure
rate of CQ monotherapy over 28 d was 22.6% in this study,
and thus CQ is no longer useful as ﬁrst-line treatment for
malaria in children. The combination CQ/SP is an efﬁcacious
treatment for uncomplicated malaria in Gambian children,
but the high prevalence of CQ-resistant parasites coupled
with a small but measurable SP failure rate strongly suggest
that this level of efﬁcacy is unsustainable in our study area.
These data were collected in late 2001, and continued use of
CQ/SP as ﬁrst-line treatment may have further eroded the
efﬁcacy of this combination since that time. However,
subsequent studies show that crude parasitological efﬁcacy
for CQ/SP in Farafenni has remained good at 88% in 2002
[11] and 86% in 2003 (P. Milligan and S. Dunyo, unpublished
data). CQ/SP has been the ﬁrst-line antimalarial regimen in
the Gambia since 2004.
In 1995, Bojang et al. [8] measured the parasitological
efﬁcacy of SP and CQ/SP in children aged 1–10 y presenting
to health facilities at Sibanor and Basse, the Gambia. These
authors found the cumulative (uncorrected) parasitological
failure rate at day 28 was 10% for SP (15 of 150) and 5% (7 of
141) for CQ/SP. These compare with uncorrected rates of
17.6% (29 of 165) and 13.9% (24 of 173) in the present study.
Assuming the methodologies used are compatible, this
suggests that children treated with SP in 2001 had a relative
risk of parasitological failure of 1.31 (p¼ 0.053) compared to
children treated with SP in 1995. Children treated with CQ/
SP in 2001 had a relative risk of failure of 1.47 (p¼0.009). This
exploratory comparison does suggest that the efﬁcacy of both
SP and CQ/SP has diminished in the 5-y period between these
two studies. Bojang et al. did ﬁnd that CQ/SP provided more
rapid resolution of malaria symptoms than treatment with SP
alone, but this was not tested in our study.
We used msp2 genotyping in a subset of parasitological
treatment failures to estimate the recrudescence rate in each
treatment group. This method is prone to underestimate the
true number of recrudescent infections in areas of stable
transmission, because the PCR method will not pick up
minority genotypes that may be present in the pretreatment
sample at low abundance. A multiplicity of infection is seen
in most infected patients in sub-Saharan Africa, and, among
children enrolled in our study, there were on average four
genotypes per infection prior to treatment (R. Ord and C. J.
Sutherland, unpublished data). Minority genotypes that are
resistant may ﬂourish under drug selection and become
dominant during follow-up. These will appear to be a ‘‘new’’
infection, but are actually recrudescent [20]. Thus PCR
correction must be interpreted carefully, and for this reason
we prefer to project a comparative estimate of the true
failure rate among the treatment groups, rather than assign
each posttreatment parasitaemia its own status as a recru-
descent or a new infection.
.......................................................................................................................................................................................
Table 5. Odds of Subsequent Treatment Failure for Each Single-Locus Genotype, the pfdhfr Triple Mutant, and the Four-Locus
Genotypes TFRG and TYRG at Day 0, in Each Treatment Group
OR (95% CI)a CQ SP CQ/SP
Pfcrt-76T 1.2 (0.098–9.05) p* ¼ 1.0 1.76 (0.322–10.2) p ¼ 0.48 0.57 (0.10–3.06) p ¼ 0.49
Pfmdr1-86Y 1.24 (0.151–15.4) p ¼ 1.0 2.75 (0.699–11.0) p ¼ 0.13 2.56 (0.698–9.58) p ¼ 0.15
Pfmdr1-184F 0 (0–4.32) p ¼ 1.0 2.88 (0.353–34.6) p ¼ 0.38 0.76 (0.051–11.4) p ¼ 1.0
Pfdhfr-51I 3.38 (0.252–52.3) p ¼ 0.33 — (zero denominator) p ¼ 0.16 2.05 (0.297–23.5) p ¼ 0.69
Pfdhfr-59R 1.3 (0.104–10.0) p ¼ 1.0 6.76 (0.645–333) p ¼ 0.09 2.23 (0.525–11.2) p ¼ 0.35
Pfdhfr-108N 0.548 (0.010–5.99) p ¼ 1.0 2.65 (0.362–30.7) p ¼ 0.41 0.75 (0.147–4.30) p ¼ 0.72
Pfdhps-437G 1.5 (0.187–10.4) p ¼ 0.68 7.33 (1.45–47.2) p ¼ 0.009 1.90 (0.560–6.59) p ¼ 0.28
Pfdhfr triple, IRN 2.0 (0.173–22.3) p ¼ 0.63 — (zero denominator) p ¼ 0.16 2.65 (0.384–30.0) p ¼ 0.43
76T/86Y 1.0 (0.120–12.7) p ¼ 1.0 4.15 (1.01–17.8) p ¼ 0.036 1.75 (0.485–6.32) p ¼ 0.40
59R/437G 0.75 (0.096–5.17) p ¼ 1.0 7.20 (1.60–36.8) p ¼ 0.005 2.05 (0.615–6.89) p ¼ 0.28
TYRG 0.43 (0.050–5.85) p ¼ 0.58 16.7 (1.83–758) p ¼ 0.004 2.27 (0.584–8.99) p ¼ 0.23
a Comparator groups are as follows: pretreatment parasite isolates from 61 of 90 randomly selected patients, because 29 of these patients subsequently failed treatment and from 100
patients who failed treatment during the follow-up period of 28 d.
* Two-sided Fisher exact test.
Statistically significant p values are indicated in bold.
DOI: 10.1371/journal.pctr.0010014.t005..
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In our study area, addition of SP to CQ provided a
therapeutic efﬁcacy of over 90% after PCR correction [6; this
study], and is currently the recommended regimen in the
Gambia. SP alone also provides parasitological efﬁcacy of
approximately 90% over 28 d [9; this study]. We were
therefore surprised to ﬁnd high prevalences of both the
pfdhfr ‘‘IRN’’ triple mutant and the pfdhps-437G allele in our
pretreatment population. The absence of the pfdhfr-164L and
pfdhps-540E mutations in this study area (R. Hallett, R. Ord,
and A. Randall, unpublished data) may explain why a
reasonable level of SP efﬁcacy is retained, although a lack
of correlation between mutations and outcomes in individual
patients is frequently observed in clinical trials of antima-
larial treatment [25,26]. Nevertheless, the single marker
pfdhps-437G was strongly associated with SP treatment failure
in univariate analyses (Table 5).
Generalizability
Our study suffered from a high dropout rate due to logistic
constraints exacerbated by national elections in the Gambia
in October 2001, which meant that many staff and
participants traveled away from the study area. Nevertheless,
estimates of efﬁcacy were consistent with other studies in
the area in 1998 and 1999 (SP) [13], in 1998 and 2000 (CQ)
[6,13], and in 2002 and 2003 (CQ/SP) [11]. Therefore, ﬁnding
that SP and CQ/SP are efﬁcacious treatments despite the
common occurrence of resistance-associated genotypes in
four genes of interest is likely to be generally true.
Multidrug-resistant parasite genotypes have recently been
described in a single case report from South Africa [27], but
have not been widely investigated in African parasite
populations, nor has the impact of such genotypes on
treatment outcomes been measured in clinical trials. We
found that P. falciparum parasites with the multidrug-
resistant genotype TYRG, deﬁned at the four loci pfcrt-76,
pfmdr1-86, pfdhfr-59, and pfdhps-437 respectively, are rela-
tively common among Gambian children presenting with
uncomplicated malaria. The TYRG genotype was associated
with therapeutic failure after treatment with SP, but not
with the combination CQ/SP. Unexpectedly, there was also a
weak association between SP treatment failure and the
carriage of CQ resistance-associated alleles of pfcrt and
pfmdr1. This may reﬂect the relatively low power of our
study, and the exploratory nature of our analyses, which did
not correct for multiple testing. Furthermore, the high
prevalence of pfcrt-76T in the parasite population is likely to
have masked associations between CQ-resistance loci and
treatment outcomes. Nevertheless, these preliminary results
do demonstrate the need for carefully designed studies to
measure the contribution of multidrug-resistant parasites to
inadequate treatment of uncomplicated malaria in African
children as combination treatments become more widely
deployed. Inadequate treatment is likely to increase risk of
progression to severe disease, particularly severe malarial
anaemia [17], and thus short-term gains in terms of
improved treatment efﬁcacy achieved with combinations
such as CQ/SP and amodiaquine/SP may be quickly eroded if
multidrug-resistant genotypes enjoy a selective advantage in
the treated host. In the accompanying paper, we investigate
the nature of that selective advantage in Anopheles gambiae
mosquitoes experimentally fed on gametocytes from chil-
dren who had received the CQ/SP combination [18]. The
results suggest that children harbouring multidrug-resistant
parasites are signiﬁcantly more infectious to mosquitoes
than other CQ/SP-treated children.
Overall Evidence
A recent systematic review found a poor evidence base for the
therapeutic efﬁcacy of CQ/SP [28], yet this drug combination
has been ﬁrst-line therapy for uncomplicated malaria in the
Gambia since 2004. We have identiﬁed multidrug-resistant
parasite genotypes of P. falciparum carrying alleles implicated
in resistance to both CQ and SP, and found these to be
common in our study area in 2001. Nevertheless, these
parasites did not substantially challenge the therapeutic
efﬁcacy of SP or CQ/SP in this study, which were found to
have 82.4 and 86.1% efﬁcacy against recurrent parasitaemia,
respectively. The prevalence of these genotypes suggests they
are advantageous to the parasite. Therefore, continued use of
CQ/SP may favour an increase in the prevalence of SP
resistance-associated alleles, and should the absent pfdhps-
540E mutation be introduced to the population the efﬁcacy
of the combination may then drastically decline [25]. The risk
of this occurring is heightened by the prevalence of CQ-R
parasites in the Gambia [15–17; this study], such that SP has
been added to a drug that is already failing. It has been
demonstrated that the addition of artesunate to CQ produces
a poor therapeutic combination [6]. A possible interim
solution in the Gambia for the period leading up to
implementation of ACTs may be amodiaquine plus SP, a
combination found to work very well in other settings where
CQ resistance is high but amodiaquine remains efﬁcacious
[29].
SUPPORTING INFORMATION
CONSORT Checklist
Found at DOI: 10.1371/journal.pctr.0010014.sd001 (50 KB DOC).
Trial Protocol
Found at DOI: 10.1371/journal.pctr.0010014.sd002 (88 KB DOC).
ACKNOWLEDGMENTS
We thank all of the parents and guardians of the patients, and the
children themselves, for their willing cooperation. We are grateful to
the North Bank East Divisional Health Team and the staff of
Farafenni Maternal and Child Health Clinic for invaluable assistance.
Thanks are also extended to Yorro Bah and the Medical Research
Council team of ﬁeld and laboratory assistants for their excellent
technical assistance. We are grateful to Paul Milligan for generating
the allocation list.
Author Contributions
SD, CS, GAT, MP, and NA designed the study and participated in the
statistical analysis and drafting of the manuscript. SD, CS, RO, GW,
RC, and EM carried out the ﬁeld study. CS and RO coordinated ﬁeld
and laboratory procedures. RH, RO, and CS performed genotyping
experiments and analysed molecular genetic data. MJ carried out
laboratory procedures and assisted in supervision of ﬁeld staff. MS
managed the data.
REFERENCES
1. World Health Organization [WHO] (1993) Implementation of the global
malaria control strategy. Geneva: World Health Organization. Technical
Report Series Number 839.
www.plosclinicaltrials.org July | 2006 | e140009
Multidrug-Resistant Malaria in the Gambia
2. World Health Organization [WHO], United Nations Children’s Fund
[UNICEF] (2003) Africa Malaria Report 2003. World Health Organization,
Geneva (WHO/CDS/MAL/2003.1093). Available: http://www.rbm.who.int/
amd2003/amr2003/amr_toc.htm. Accessed: 12 February 2005.
3. Greenwood BM, Bradley AK, Byass P, Greenwood AM, Menon A, et al.
(1990) Evaluation of a primary health care programme in The Gambia. II.
Its impact on mortality and morbidity in young children. J Trop Med Hyg
93: 87–97.
4. Wellems TE, Plowe CV (2001) Chloroquine-resistant malaria. J Infect Dis
184: 770–776.
5. Mu¨ller O, Boele van Hensbroek M, Jaffa S, Drakeley C, Okorie C, et al.
(1996) A randomized trial of chloroquine, amodiaquine and pyrimeth-
amine-sulfadoxine in Gambian children with uncomplicated malaria. Trop
Med Int Health 1: 124–132.
6. Sutherland CJ, Drakeley CJ, Obisike U, Coleman R, Jawara M, et al. (2003)
The addition of artesunate to chloroquine for treatment of Plasmodium
falciparum malaria in Gambian children delays, but does not prevent
treatment failure. Am J Trop Med Hyg 69: 19–25.
7. White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, et al. (1999)
Averting a malaria disaster. Lancet 353: 1965–1967.
8. Bojang KA, Schneider G, Forck S, Obaro SK, Jaffar S, et al. (1996) A trial of
Fansidart plus chloroquine or Fansidart alone for the treatment of
uncomplicated malaria in Gambian children. Trans R Soc Trop Med Hyg
92: 73–76.
9. von Seidlein L, Bojang K, Jones P, Jaffar S, Pinder M, et al. (1998) A
randomized controlled trial of artemether/benﬂumetol, a new antimalarial
and pyrimethamine/sulfadoxine in the treatment of uncomplicated
falciparum malaria in African children. Am J Trop Med Hyg 58: 638–644.
10. von Seidlein L, Milligan P, Pinder M, Bojang K, Anyalebechi C, et al. (2000)
Efﬁcacy of artesunate plus pyrimethamine-sulphadoxine for uncompli-
cated malaria in Gambian children: a double-blind, randomised, controlled
trial. Lancet 355: 352–357.
11. Sutherland CJ, Ord R, Dunyo S, Jawara M, Drakeley CJ, et al. (2005)
Reduction of malaria transmission to Anopheles mosquitoes with a six-dose
regimen of Co-Artemether. PLoS Med 2: 338–346.
12. Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, et al. (2005)
Amodiaquine alone, amodiaquineþsulfadoxine-pyrimethamine, amodia-
quineþartesunate, and artemether-lumefantrine for outpatient treatment
of malaria in Tanzanian children: a four-arm randomised effectiveness
trial. Lancet 365: 1474–1480.
13. Targett G, Drakeley C, Jawara M, von Seidlein L, Coleman R, et al. (2001)
Artesunate reduces but does not prevent posttreatment transmission of
Plasmodium falciparum to Anopheles gambiae. J Infect Dis 183: 1254–1259.
14. Drakeley CJ, Jawara M, Targett GA, Walraven G, Obisike U, et al. (2004)
Addition of artesunate to chloroquine for treatment of Plasmodium
falciparum malaria in Gambian children causes a signiﬁcant but short-lived
reduction in infectiousness for mosquitoes. Trop Med Int Health 9: 53–61.
15. Sutherland CJ, Alloueche A, Curtis J, Drakeley CJ, Ord R, et al. (2002)
Gambian children successfully treated with chloroquine can harbour and
transmit Plasmodium falciparum gametocytes carrying resistance genes. Am J
Trop Med Hyg 67: 578–585.
16. Hallett RL, Sutherland CJ, Alexander N, Ord R, Jawara M, et al. (2004)
Combination therapy counteracts the enhanced transmission of drug-
resistant malaria parasites to mosquitoes. Antimicrob Agents Chemother
48: 3940–3943.
17. Meerman L, Ord R, Teun Bousema J, van Niekerk M, Osman E, et al. (2005)
Carriage of chloroquine-resistant parasites and delay of effective treatment
increase the risk of severe malaria in Gambian children. J Infect Dis 192:
1651–1657.
18. Hallett RL, Dunyo S, Ord R, Jawara M, Pinder M, et al. (2006) Chloroquine/
Sulphadoxine-Pyrimethamine for Gambian Children with malaria: Trans-
mission to Mosquitoes of Multidrug-Resistant Plasmodium falciparum.
PLoS Clin Trials 1: e15.
19. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE (1995) Pyrimeth-
amine and proguanil resistance-conferring mutations in Plasmodium
falciparum dihydrofolate reductase: polymerase chain reaction methods
for surveillance in Africa. Am J Trop Med Hyg 52: 565–568.
20. Snounou G, Beck H-P (1998) The use of PCR genotyping in the assessment
of recrudescence or reinfection after antimalarial drug treatment. Parasitol
Today 14: 462–467.
21. Cattamanchi A, Kyabayinze D, Hubbard A, Rosenthal PJ, Dorsey G (2003)
Distinguishing recrudescence from reinfection in a longitudinal antima-
larial drug efﬁcacy study: comparison of results based on genotyping msp-
1, msp-2 and glurp. Am J Trop Med Hyg 68: 133–139.
22. Pearce RJ, Drakeley C, Chandramohan D, Mosha F, Roper C (2003)
Molecular determination of point mutation haplotypes in the dihydrofo-
late reductase and dihydropteroate synthase of Plasmodium falciparum in
three districts of northern Tanzania. Antimicrob Agent Chemother 47:
1347–1354.
23. Cisse´ B, Sokhna C, Boulanger D, Milet J, Baˆ EH, et al. (2006) Seasonal
intermittent preventive treatment with artesunate and sulfadoxine
pyrimethamine reduces the burden of malaria in Senegalese children.
Lancet 367: 659–667.
24. Kahn H, Sempos C (1989) Statistical methods in epidemiology. New York:
Oxford University Press. 320 p.
25. Dorsey G, Dokomajilar C, Kiggundu M, Staedke SG, Kamya MR, et al. (2004)
Principal role of dihydropteroate synthase mutations in mediating
resistance to sulfadoxine-pyrimethamine in single-drug and combination
therapy of uncomplicated malaria in Uganda. Am J Trop Med Hyg. 71: 758–
763.
26. Mendez F, Munoz A, Carrasquilla G, Jurado D, Arevalo-Herrera M, et al.
(2002) Determinants of treatment response to sulfadoxine-pyrimethamine
and subsequent transmission potential in falciparum malaria. Am J
Epidemiol 156: 230–238.
27. Schwab U, Alloueche A, Doherty JF (2005) Multidrug-resistant malaria from
South Africa. Clin Infect Dis 40: 493.
28. McIntosh HM, Jones KL (2005) Chloroquine or amodiaquine combined
with sulfadoxine-pyrimethamine for treating uncomplicated malaria.
Cochrane Database Syst Rev (4): CD000386.
29. Staedke SG, Mpimbaza A, Kamya MR, Nzarubara BK, Dorsey G, et al. (2004)
Combination treatments for uncomplicated falciparum malaria in Kam-
pala, Uganda: randomised clinical trial. Lancet 364: 1950–1957.
www.plosclinicaltrials.org July | 2006 | e140010
Multidrug-Resistant Malaria in the Gambia
